Latest news with #Bausch&LombInc
&w=3840&q=100)
Business Standard
17-07-2025
- Business
- Business Standard
Lupin share price increases on rolling out eye medication; details here
Lupin share price: Pharmaceutical company Lupin share price rose as much as 1.31 per cent to hit an intraday high of ₹1,955 per share on Thursday, July 17, 2025. Around 10:20 AM, Lupin share price continued to trade higher, up 1.07 per cent at ₹1,950.40 per share. In comparison, BSE Sensex was trading 0.22 per cent lower at 82,456.51 levels. Why did Lupin share price rise today? Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market. In a press release, the company said, 'Global pharma major Lupin Limited (Lupin) today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent is bioequivalent to Lotemax Ophthalmic Suspension, 0.5 per cent, of Bausch & Lomb Inc.' The drug is a generic version of Bausch & Lomb's Lotemax, and is used to treat steroid-responsive inflammatory conditions of the eye, including conjunctivitis, keratitis, iritis, and post-operative inflammation. According to IQVIA MAT data for May 2025, the reference listed drug (RLD) Lotemax had estimated annual sales of around USD 55 million in the US. Track Stock Market LIVE Updates Lupin Q4 results The pharma major Lupin reported a 112.4 per cent year-on-year (Y-o-Y) jump in consolidated net profit at ₹782.4 crore for Q4FY25, compared to ₹368.2 crore in the year-ago period. Revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, up from ₹4,961 crore in Q4FY24. However, on a sequential basis, profit declined 8.9 per cent and revenue slipped 1.7 per cent. Operationally, Ebitda grew 34.3 per cent Y-o-Y to ₹1,371 crore, while the Ebitda margin improved to 24.8 per cent from 21 per cent in the same quarter last year. About Lupin Lupin is among the leading Indian multinational pharmaceutical companies headquartered in Mumbai, known for its expertise in developing and commercialising generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). With operations spanning over 100 countries, including key markets like the US, India, South Africa, and regions across Asia Pacific, Latin America, Europe, and the Middle East, Lupin has established itself as a global player. The company holds strong positions in therapeutic areas such as cardiovascular, diabetology, asthma, paediatrics, and central nervous system (CNS) disorders. Notably, it is also a global leader in anti-tuberculosis and cephalosporin segments. Founded in 1968 by Desh Bandhu Gupta with a mission to combat life-threatening infectious diseases, Lupin has grown into a pharmaceutical powerhouse with a robust global footprint. It operates multiple manufacturing facilities in India, including sites at Mandideep, Ankleshwar, Tarapur, and Vadodara, supported by a network of research centers and a large workforce. In addition to its pharmaceutical business, the company has expanded into diagnostics through its wholly owned subsidiary, Lupin Diagnostics, which operates a national reference laboratory in Navi Mumbai.
The Hindu
16-07-2025
- Business
- The Hindu
Lupin launches copy of Bausch & Lomb's ophthalmic drug
Generic drugmaker Lupin has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States, a product bioequivalent to Bausch & Lomb Inc's Lotemax Ophthalmic Suspension, 0.5%. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is used in treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea and superficial punctate keratitis. It is also indicated for the treatment of post-operative inflammation following ocular surgery, Lupin said on Wednesday in a release on the launch. The product (reference listed drug Lotemax) had estimated annual sales of $55 million in the U.S., it said citing IQVIA MAT May 2025 numbers.
Business Standard
16-07-2025
- Health
- Business Standard
Lupin launches Loteprednol Etabonate Ophthalmic Suspension in US
Lupin today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. It is also indicated for the treatment of post-operative inflammation following ocular surgery.
Business Standard
16-07-2025
- Business
- Business Standard
Lupin launches Loteprednol Etabonate Ophthalmic Suspension in the United States
Lupin announced that it has launched Loteprednol Etabonate Ophthalmic Suspension in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic Suspension, 0.5%, of Bausch & Lomb Inc. Loteprednol Etabonate Ophthalmic Suspension is indicated for the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Additionally, the drug is indicated for managing post-operative inflammation following ocular surgery. According to IQVIA MAT data for May 2025, the reference product, Lotemax, recorded annual U.S. sales of approximately USD 55 million. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The companys consolidated net profit surged 114.9% to Rs 772.52 crore on a 13.6% jump in net sales to Rs 5,562.20 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.04% to Rs 1,931.01 on the BSE.
The Hindu
01-07-2025
- Business
- The Hindu
Lupin gets U.S. FDA nod for Loteprednol Etabonate Ophthalmic Gel
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug application for Loteprednol Etabonate Ophthalmic Gel, 0.38% The approved product is bioequivalent to Lotemax SM Ophthalmic Gel of Bausch & Lomb Inc. Lupin is the exclusive first-to-file for the product and consequently eligible for 180 days of generic drug exclusivity. The product will be manufactured at its Pithampur facility, the company said. Loteprednol Etabonate Ophthalmic Gel, 0.38% (RLD Lotemax SM) had an estimated annual sale of $29 million in the U.S., it said citing IQVIA MAT May 2025 numbers. A corticosteroid, the drug is indicated for treatment of postoperative inflammation and pain following ocular surgery.
